Bead injection ELISA for the determination of antibodies implicated in type 1 diabetes mellitus.

This work introduces a novel analytical method for the detection and study of GAD65 autoantibodies, which have been implicated in the onset of type 1 diabetes. There is a clinical need for a rapid and automated assay for GAD65 autoantibodies. Therefore, this method was designed to exploit the advantages of bead injection (BI) analysis for enzyme-linked immunosorbent assays (ELISA). BI ELISA is a microscale technique that uses enzyme labeled secondary antibodies to detect the capture of target antibodies on immobilized antigen in the flow cell of the lab-on-valve (LOV) manifold. A detection limit of 20 ng mL(-1) of GAD65 monoclonal antibody 144 compares favorably with the sensitivity and precision of a standard ELISA currently employed to detect GAD65 autoantibodies. Compared to the standard ELISA protocol, BI ELISA offers a significantly reduced assay time and complete automation of solution handling and detection.

[1]  P. Tighe,et al.  Distinct antigenic features of linear epitopes at the N‐terminus and C‐terminus of 65 kDa glutamic acid decarboxylase (GAD65): implications for autoantigen modification during pathogenesis , 2002, Clinical and experimental immunology.

[2]  J. Walikonis,et al.  Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. , 1998, Mayo Clinic proceedings.

[3]  M. Papouchado,et al.  Highly-sensitive and specific enzyme-linked immunosorbent assays for GAD65 autoantibodies using a thioredoxin-GAD65 fusion antigen. , 1997, Journal of immunological methods.

[4]  Å. Lernmark.  Glutamic Acid Decarboxylase – Gene to Antigen to Disease , 1996, Journal of internal medicine.

[5]  J. Ruzicka,et al.  Label dilution method: a novel tool for bioligand interaction studies using bead injection in the lab-on-valve format. , 2002, The Analyst.

[6]  S. Miyamoto,et al.  Clinical significance and time course of antibodies to glutamic acid decarboxylase in Japanese children with type I (insulin‐dependent) diabetes mellitus , 1996, Acta paediatrica.

[7]  K. Eguchi,et al.  Autoantibodies to IA‐2 in Type 1 Diabetes , 2002, Annals of the New York Academy of Sciences.

[8]  P. Hodder,et al.  Automation of functional assays by flow injection fluorescence microscopy. , 1999, Trends in biotechnology.

[9]  Jaromir Ruzicka,et al.  Real-time determination of glucose consumption by live cells using a lab-on-valve system with an integrated microbioreactor. , 2002, The Analyst.

[10]  N. Morgenthaler,et al.  Antibodies against glutamic acid decarboxylase: prevalence in neurological diseases , 2001, Journal of neurology, neurosurgery, and psychiatry.

[11]  J. Ruzicka.  Lab-on-valve: universal microflow analyzer based on sequential and bead injection , 2000 .

[12]  L. Harrison,et al.  IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. , 1998, Human immunology.

[13]  W. Scherbaum,et al.  Comparison of a new anti-glutamic acid decarboxylase (GAD) enzyme-linked immunosorbent assay (ELISA) with radioimmunoassay methods: a multicenter study. , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[14]  Y. Matsuzawa,et al.  High prevalence of antibodies to glutamic acid decarboxylase in comparison to islet cell antibodies in patients with long-standing insulin-dependent diabetes mellitus. , 1996, Research communications in molecular pathology and pharmacology.

[15]  Å. Lernmark,et al.  Stable GAD65 autoantibody epitope patterns in type 1 diabetes children five years after onset. , 2002, Journal of autoimmunity.

[16]  Å. Lernmark,et al.  A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM , 1994, Diabetologia.

[17]  P. Fernlund,et al.  Measurement of antibodies against glutamic acid decarboxylase 65 (GADA): two new 125I assays compared with [35S]GAD 65-ligand binding assay. , 1997, Clinical chemistry.